Volume 31, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


The book is divided into five sections with a total of 21 chapters. The first section, which is one-third of the book, is an overview of the mycoses in general, and a summary of all of the most useful antifungal agents currently available, including the imidazoles (the chemical group to which ketoconazole belongs), with considerations of their current uses and what is known of the mechanism of action of each. The other four sections deal with ketoconazole specifically and include the pharmacology of the drug, clinical experience in the treatment of superficial and deep mycoses, and some practical aspects of treatment. Much of the experimental data presented in the book is unpublished elsewhere and is housed in the Janssen Research Foundation, Beerse, Belgium, since Janssen Pharmaceutica is the manufacturer of the drug. As this specific imidazole is relatively new there has not been time for large clinical trials, including long-term follow-up for relapse as well as potential side effects of long-term therapy, especially with doses higher than those initially recommended for use, and the reader of the book must be cautious, therefore, when thawing conclusions from the data presented.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error